Home
Subscription
December 2024 issue
November 2024 issue
October 2024 issue
September 2024 issue
August 2024 issue
July 2024 issue
June 2024 issue
May 2024 issue
April 2024 issue
April 1, 2024 issue
March 2024 issue
February 2024 issue
January 2024 issue
BACK ISSUES
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
|
2012 Issues
December 2012 Issue
• A Christmas Letter
• New Drug Review: Mirabegron (Myrbetriq)
• Index for 2012
November 2012 Issue
• Feature - Pharmacy-Assisted Suicide - at CVS, Rite Aid, Walgreens, Walmart, etc.
• New Drug Review: Tofacitinib citrate (Xeljanz)
October 2012 Issue
• Feature - The Meningitis Tragedy - More Regulation is Not the Answer
• New Drug Review: Elvitegravir/Cobicistat (Stribild)
September 2012 Issue
• Feature - Our Professional Autonomy and the Health of our Patients are at Risk! We Need More Independence in our Practice Responsibilities and More Independent Pharmacies
• New Drug Review: Peginesatide acetate (Omontys)
August 2012 Issue
• Feature - Accreditation of Community Pharmacies Can Have Important Benefits - But the Program Must Have Credibility and Value for the Participants
• New Drug Review: Spinosad (Natroba)
July 2012 Issue
• Feature - The Restrictive and Risky Mail-order Distribution Program for Qsymia Must be Rescinded
• New Drug Review: Ezogabine (Potiga)
June 2012 Issue
• Feature - Is Patient Safety at Risk at CVS? There is a Whistleblower!
• New Drug Review: Aflibercept (Eylea)
May 2012 Issue
• Feature - The "Tyranny of the Urgent" Must Not Compromise our Commitment to our Priorities
• New Drug Review: Ingenol mebutate (Picato)
April 2012 Issue
• Feature - We Must Prevent "Reform" from Taking the "Care" out of Health Care!
• New Drug Review: Indacaterol maleate (Arcapta)
March 2012 Issue
• Feature - Many Prescription Medications Should be Available Without a Prescription from a Pharmacist
• New Drug Review: Fidaxomicin (Dificid)
February 2012 Issue
• Feature - CVS - Criminal Charges are Needed!
• New Drug Review: Roflumilast (Daliresp)
January 2012 Issue
• Feature - Pharmacy Must Establish its Own Prescription Benefit Program
• New Drug Review: Belimumab (Benlysta)
| |
